Novavax
Clinical trials sponsored by Novavax, explained in plain language.
Novavax
NVAX
NASDAQ
A vaccine company known for its COVID-19 vaccine and other infectious disease vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New novavax JN.1 vaccine trial aims to protect adults 50-64 from COVID Results expected Nov 2026 (estimated)